Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher R deFilippi

Showing results (21-30 of 158) with videos related to

Pageof 16
Sort By:
JACC. Heart Failure|March 9, 2023
Redefining Pre-Heart Failure With Cardiac Biomarkers: Clinical and Research ImplicationsPalak Shah, Rafael Arias, Christopher R deFilippi
Circulation|October 16, 2020
Navigating COVID-19 Testing: Special Considerations for the Cardiovascular ClinicianPalak Shah, Christopher R deFilippi, Kristin E Mullins
Circulation|July 18, 2018
Designing a Better Mousetrap: Reflections on the November 28, 2017, US Food and Drug Administration Meeting on Next-Generation "High-Sensitivity" Cardiac Troponin Assays to Diagnose Myocardial InfarctionJames McCord, L Kristin Newby, Christopher R deFilippi
Coronary Artery Disease|October 17, 2013
Interpreting cardiac troponin results from highly sensitive assays in patients with chronic kidney disease: acute coronary syndromes and beyondChristopher End, Stephen L Seliger, Christopher R deFilippi
Circulation|January 22, 2019
Response by McCord et al to Letter Regarding Article, "Designing a Better Mousetrap: Reflections on the November 28, 2017, US Food and Drug Administration Meeting on Next-Generation "High-Sensitivity" Cardiac Troponin Assays to Diagnose Myocardial Infarction"James McCord, L Kristin Newby, Christopher R deFilippi
Annals of Emergency Medicine|October 24, 2020
In replyRichard M Nowak, William F Peacock, Christopher R deFilippi
Clinical Biochemistry|January 25, 2015
Use and interpretation of high sensitivity cardiac troponins in patients with chronic kidney disease with and without acute myocardial infarctionRavi H Parikh, Stephen L Seliger, Christopher R deFilippi
Clinical Chemistry|April 8, 2011
Highly sensitive troponin assays and the cardiology community: a love/hate relationship?James A de Lemos, David A Morrow, Christopher R deFilippi
Clinical Chemistry|June 26, 2007
Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortalityChristopher R deFilippi, Stephen L Seliger, Susan Maynard, et al.
The American Journal of Cardiology|February 11, 2015
Soluble ST2 testing in the general populationJennifer E Ho, Piyamitr Sritara, Christopher R deFilippi, et al.
Pageof 16

Showing results (21-30 of 158) with videos related to

Sort By:
Pageof 16
JACC. Heart Failure|March 9, 2023
Redefining Pre-Heart Failure With Cardiac Biomarkers: Clinical and Research ImplicationsPalak Shah, Rafael Arias, Christopher R deFilippi
Circulation|October 16, 2020
Navigating COVID-19 Testing: Special Considerations for the Cardiovascular ClinicianPalak Shah, Christopher R deFilippi, Kristin E Mullins
Circulation|July 18, 2018
Designing a Better Mousetrap: Reflections on the November 28, 2017, US Food and Drug Administration Meeting on Next-Generation "High-Sensitivity" Cardiac Troponin Assays to Diagnose Myocardial InfarctionJames McCord, L Kristin Newby, Christopher R deFilippi
Coronary Artery Disease|October 17, 2013
Interpreting cardiac troponin results from highly sensitive assays in patients with chronic kidney disease: acute coronary syndromes and beyondChristopher End, Stephen L Seliger, Christopher R deFilippi
Circulation|January 22, 2019
Response by McCord et al to Letter Regarding Article, "Designing a Better Mousetrap: Reflections on the November 28, 2017, US Food and Drug Administration Meeting on Next-Generation "High-Sensitivity" Cardiac Troponin Assays to Diagnose Myocardial Infarction"James McCord, L Kristin Newby, Christopher R deFilippi
Annals of Emergency Medicine|October 24, 2020
In replyRichard M Nowak, William F Peacock, Christopher R deFilippi
Clinical Biochemistry|January 25, 2015
Use and interpretation of high sensitivity cardiac troponins in patients with chronic kidney disease with and without acute myocardial infarctionRavi H Parikh, Stephen L Seliger, Christopher R deFilippi
Clinical Chemistry|April 8, 2011
Highly sensitive troponin assays and the cardiology community: a love/hate relationship?James A de Lemos, David A Morrow, Christopher R deFilippi
Clinical Chemistry|June 26, 2007
Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortalityChristopher R deFilippi, Stephen L Seliger, Susan Maynard, et al.
The American Journal of Cardiology|February 11, 2015
Soluble ST2 testing in the general populationJennifer E Ho, Piyamitr Sritara, Christopher R deFilippi, et al.
Pageof 16